Trading Biotech Breakthroughs

Wednesday, 18 Nov 2009 | 5:45 PM ET

The latest erectile dysfunction drug is showing promise of working even faster than those already on the market.

Developed by Vivus, the new drug called Avanafil works by inhibiting the PDE5 enzyme, the same as Pfizer's Viagra and Eli Lilly's Cialis. But Vivus said it’s drug acts faster than its rivals.

Considering sales of current erectile dysfunction therapies total more than $3.5 billion a year, what’s the trade?

I think Vivus is a stock to watch, says Pete Najarian. I wouldn’t be a buyer on this news but definitely keep on eye on the firm. They also have a weight loss drug in the pipeline that could deliver.

I’d forget this erectile dysfunction stuff, says Guy Adami. Instead I like Amgen on a pullback.

Biotech Breakthroughs
The Fast Money team ponders whether Vivus is a threat to other ED drug makers.

Got something to to say? Send us an e-mail at fastmoney-web@cnbc.com and your comment might be posted on the Rapid Recap. If you'd prefer to make a comment but not have it published on our website send those e-mails to fastmoney@cnbc.com.

CNBC.com with wires

  Price   Change %Change


Contact Fast Money

  • Showtimes

    Halftime Report - Weekdays 12p ET
    Fast Money - Weekdays 5p ET
  • Melissa Lee is the host of CNBC's “Fast Money” and “Options Action.”

  • Scott Wapner is host of the "Fast Money Halftime Report," which airs weekdays from 12 p.m. to 1 p.m. ET.

  • Guy Adami is a contributor on CNBC's "Fast Money." He also is managing director of stockMONSTER.com.

  • Najarian, the "Pit Boss," is cofounder of optionMONSTER.com, a news site for options traders.

  • Finerman is president of Metropolitan Capital Advisors, Inc., a company she co-founded.

  • Founder of EmergingMoney.com

  • Chief Market Strategist for Virtus Investment Partners & CNBC Contributor

Halftime Report